Eli Lilly’s ongoing research collaboration with Peptron, initiated via a 2024 material transfer agreement for evaluating SmartDepot’s sustained-release microsphere technology on peptide candidates, remains in the feasibility-assessment stage without any announced commercial license. The evaluation period, extended to a maximum of 24 months through late 2026, focuses on technical validation rather than binding rights transfer, while Lilly has already executed a separate long-acting formulation deal with Camurus. Recent July 2026 statements from Peptron confirm the joint work continues on track but provide no signals of imminent commercialization, and market reaction to related news reflected tempered expectations. With the October 7 resolution date approaching and no disclosed progress toward a formal technology-transfer agreement, traders assign an 87.5% implied probability to “No,” reflecting the absence of catalysts that would typically precede such a licensing milestone.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
13% probabilità
$11,264 Vol.
$11,264 Vol.
7 ott 2026
13% probabilità
$11,264 Vol.
$11,264 Vol.
7 ott 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing research collaboration with Peptron, initiated via a 2024 material transfer agreement for evaluating SmartDepot’s sustained-release microsphere technology on peptide candidates, remains in the feasibility-assessment stage without any announced commercial license. The evaluation period, extended to a maximum of 24 months through late 2026, focuses on technical validation rather than binding rights transfer, while Lilly has already executed a separate long-acting formulation deal with Camurus. Recent July 2026 statements from Peptron confirm the joint work continues on track but provide no signals of imminent commercialization, and market reaction to related news reflected tempered expectations. With the October 7 resolution date approaching and no disclosed progress toward a formal technology-transfer agreement, traders assign an 87.5% implied probability to “No,” reflecting the absence of catalysts that would typically precede such a licensing milestone.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Mercato aperto: May 5, 2026, 8:02 PM ET
Volume
$11,264Data di fine
7 ott 2026Mercato aperto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing research collaboration with Peptron, initiated via a 2024 material transfer agreement for evaluating SmartDepot’s sustained-release microsphere technology on peptide candidates, remains in the feasibility-assessment stage without any announced commercial license. The evaluation period, extended to a maximum of 24 months through late 2026, focuses on technical validation rather than binding rights transfer, while Lilly has already executed a separate long-acting formulation deal with Camurus. Recent July 2026 statements from Peptron confirm the joint work continues on track but provide no signals of imminent commercialization, and market reaction to related news reflected tempered expectations. With the October 7 resolution date approaching and no disclosed progress toward a formal technology-transfer agreement, traders assign an 87.5% implied probability to “No,” reflecting the absence of catalysts that would typically precede such a licensing milestone.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,264Data di fine
7 ott 2026Mercato aperto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s ongoing research collaboration with Peptron, initiated via a 2024 material transfer agreement for evaluating SmartDepot’s sustained-release microsphere technology on peptide candidates, remains in the feasibility-assessment stage without any announced commercial license. The evaluation period, extended to a maximum of 24 months through late 2026, focuses on technical validation rather than binding rights transfer, while Lilly has already executed a separate long-acting formulation deal with Camurus. Recent July 2026 statements from Peptron confirm the joint work continues on track but provide no signals of imminent commercialization, and market reaction to related news reflected tempered expectations. With the October 7 resolution date approaching and no disclosed progress toward a formal technology-transfer agreement, traders assign an 87.5% implied probability to “No,” reflecting the absence of catalysts that would typically precede such a licensing milestone.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti